Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VRTX alert in real time by email

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Stuart A. Arbuckle has been appointed as the company's Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex's Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year.

"This is an exciting time for Vertex, as we continue to expand access to our cystic fibrosis portfolio around the world and prepare to bring forward new therapies with the potential to transform the treatment of multiple serious diseases," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "Stuart built out our world-class commercial teams in both the U.S. and International and led the effort to secure the reimbursement of our medicines around the world. He also has played a key role evolving our operating model to ready us for continued expansion into new diseases and geographic areas. In his new role, Stuart will ensure that we are best positioned to maximize the potential of our innovative therapies, secure access for patients and drive continued growth for Vertex."

As Vertex's COO, Mr. Arbuckle oversees Vertex's global Commercial team, which is responsible for the company's reimbursement and access, sales, marketing, patient support, market research, as well as Commercial Manufacturing and Supply Chain, and other activities that support the approved use of Vertex's marketed medicines around the world. Mr. Arbuckle also oversees the Human Resources and Corporate Communications functions.

Mr. Arbuckle has more than 30 years of experience leading global sales and marketing efforts at biopharmaceutical companies, including at Amgen and GlaxoSmithKline plc. Mr. Arbuckle currently serves as a member of Rhythm Pharmaceuticals and ImmunoGen's board of directors, as a national board member of the Cancer Support Community, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.

Mr. Arbuckle earned a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Vertex Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second, paragraph of this press release. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Get the next $VRTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VRTX

DatePrice TargetRatingAnalyst
2/12/2025$408.00 → $424.00Sell → Hold
Canaccord Genuity
2/11/2025Sell → Hold
Canaccord Genuity
1/30/2025$460.00Overweight → Equal Weight
Wells Fargo
12/20/2024$600.00 → $535.00Buy
H.C. Wainwright
12/19/2024Outperform → Perform
Oppenheimer
12/9/2024$500.00 → $550.00Hold → Buy
Jefferies
11/14/2024$575.00Buy
Citigroup
10/16/2024Sector Perform
Scotiabank
More analyst ratings

$VRTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Vertex Announces Program Updates for Type 1 Diabetes Portfolio

    - VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - - Continue to progress multiple novel, research-stage immunoprotective approaches - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Vertex to Participate in Upcoming March Investor Conferences

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice President and Chief Financial Officer, and Dr. Altshuler will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 10:00 a.m. ET. Susie Lisa, Senior Vice Pres

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AM Best Assigns Credit Ratings to Torreyana Insurance Company, Inc.

    AM Best has assigned a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of "a" (Excellent) to Torreyana Insurance Company, Inc. (TIC) (Burlington, VT). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect TIC's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Torreyana's function as the only captive insurer for Vertex Pharmaceuticals Incorporated (Vertex) (NASDAQ:VRTX), a global pharmaceutical company. As Torreyana insures or reinsures Vertex's global liability and pr

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VRTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VRTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VRTX
SEC Filings

See more

$VRTX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

    Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VRTX
Leadership Updates

Live Leadership Updates

See more
  • Vertex Appoints Nancy Thornberry to its Board of Directors

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Vertex Appoints Michel Lagarde to its Board of Directors

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VRTX
Financials

Live finance-specific insights

See more
  • Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

    — Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S. for moderate-to-severe acute pain — — Diverse late-stage clinical pipeline accelerates with four programs in pivotal development — — Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating Officer; Duncan McKechnie, SVP and current head of North America Commercia

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcas

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

    – Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale (NPRS) – – Placebo arm showed similar within-group reduction in NPRS – – Suzetrigine was generally well tolerated – – Advancement to Phase 3 in painful lumbosacral radiculopathy planned, pending discussions with regulators – – Vertex to host investor call on December 19 at 8:00 a.m. ET – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective

    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VRTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more